Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

August 31st, 2009 AMSTERDAM - SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company. The undisclosed company's product is an innovative live biotherapeutic based anticancer drug.

August 23rd, 2009 HOERSHOLM, Denmark - - Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders - Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery - Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders. (Logo: www.newscom.com/cgi-bin/prnh/20090420/344344 ) The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets.

July 27th, 2009 COPENHAGEN, Denmark - Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline. The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads.

July 8th, 2009 LONDON - Up to GBP1000 is Available to Put Towards Training to Develop Leadership Skills. Funded by Train to Gain's Leadership & Management programme, the grants are available to companies in the UK with 5-249 staff and include: Up to GBP500 grant for owner managers, company directors.

April 27th, 2009 DUBLIN - Experts gather at medical meeting in Dublin to discuss more personalized treatment strategies Emerging research presented today at a symposium during the Society for Research on Nicotine and Tobacco (SRNT) shows that optimizing therapeutic nicotine products through new uses can significantly enhance efficacy while offering more ways of quitting. Global leaders in smoking cessation discussed clinical study and real-world results that highlight how these innovative treatment approaches go beyond the established and common uses of therapeutic nicotine to offer smokers encouraging new options in personalized quitting.(1) Studies discussed at the symposium analyzed the efficacy of using therapeutic nicotine in different ways prior to quitting, while reducing cigarette consumption, in combination with other therapeutic nicotine products, and to prevent relapse after successfully quitting.(2) Additional research assessed the use of therapeutic nicotine treatment among smokers who have not made a commitment to quit, showing that approaching quitting smoking by gradual reduction may be an effective method for this group of smokers.(3) Further, a panel of experts representing different healthcare systems across the globe highlighted innovative and effective uses of therapeutic nicotine from a clinical, regulatory, patient and system perspective.

April 19th, 2009 DENVER - Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries - DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in late stage pre-clinical studies, according to research conducted at InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology.

April 8th, 2009 SCOTTSDALE, Arizona - Additional Presentations Underscore Potency, Binding Capabilities for Antibody Pipeline And Novel Technologies - InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced today that the company will be presenting new data on its lead preclinical candidate DXL625 (CD20) for the prospective treatment of Non Hodgkin's Lymphoma (NHL) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver.

April 7th, 2009 PRINCETON, New Jersey - BioWa, Inc. announced today that it has entered into a license agreement with sanofi-aventis (EURONEXT: SAN and NYSE: SNY), providing the global healthcare company with access to BioWa's POTELLIGENT(R) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

March 22nd, 2009 SHANGHAI - Oxford Professional Training Ltd., a leading education and corporate training provider announced today that it had attracted strategic investment from The Aston Educational Group (www.astonschool.com ), an English language training organization with 60 English schools spread across 42 cities in China. UK-based training organization, Oxford Professional Limited (www.oxford-training.com ), founded in 1999 and working together with the China International Intellectech Corporation Training Center ("CTC") since 2002, is among the premier providers of learning solutions for individuals and organisations in People's Republic of China.

March 19th, 2009 COPENHAGEN - EZN3042 - a Survivin Inhibitor Jointly Developed by Enzon Pharmaceuticals and Santaris Pharma Advances into the Clinic for Patients With Solid Tumors and Lymphomas Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic. In the USA several patients with cancer have now been treated with the Company's Survivin inhibitor, which is jointly developed by Santaris Pharma and Enzon Pharmaceuticals.

April 16th, 2009 WASHINGTON - Researchers at Albany Medical College claim to have identified a potential therapeutic target for melanoma. The team led by Dr Andrew Aplin, an associate professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University, has discovered a protein called Mcl-1 that plays a critical role in melanoma cell resistance to a form of apoptosis called anoikis.

April 16th, 2009 WASHINGTON - Club moss Lycopodium serratum is a flowerless plant whose potent brew of alkaloids, which could have anti-cancer properties and may combat memory loss, have drawn considerable scientific and medical interest. Now scientists have made one of the alkaloids in a lab, in quantity sufficient for use.

July 9th, 2009 WHO approves cervical cancer vaccine CervarixLONDON — The World Health Organization has approved a second cervical cancer vaccine, this one made by GlaxoSmithKline, meaning U.N. agencies and partners can now officially buy millions of doses of the vaccine for poor countries worldwide.

April 28th, 2009 MUMBAI - GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the first quarter ended March 31. The Company has posted a net sales growth of 9.3 per cent compared to the previous quarter, while Profit Before Tax has grown by 7.9 percent, on a comparable basis.

October 1st, 2009 Talecris shares top IPO price on opening dayNEW YORK — Shares of Talecris Biotherapeutics Inc. opened their first day on the Nasdaq 2.6 percent higher than the company's IPO price and shares continued to climb throughout midday.

March 17th, 2009 WASHINGTON - For the past 25 years, researchers have tried and failed to develop an HIV vaccine, their entire focus being on a small number of engineered 'super antibodies' to fend off the virus before it takes hold. So far, these magic bullet antibodies have proved impossible to produce in people.

July 31st, 2009 BANGALORE - Two leading full service contract research organizations (CRO's), Essential CRO and Ecron Acunova today announced the formation of a global strategic alliance to strengthen the service offerings in emerging markets and help customers leverage the convergence of a broad global network. This alliance provides pharmaceutical, biotechnology, device, diagnostic and nutritional sponsors with access to 18 countries in key emerging sectors for clinical research.

March 30th, 2009 LONDON - Oxford defeated Cambridge in the 155th annual boat race. Fortunes change quickly in the Boat Race, and Saturday's was no exception.

May 12th, 2009 Mass. biotech firm explores strategic alternativesLEXINGTON, Mass. — A struggling Massachusetts biotechnology firm says it's exploring a number of strategic options, including a possible sale or a merger.

April 20th, 2009 NEW DELHI - Exuding remarkable confidence over the poll outcome, Prime Minister Manmohan Singh Monday said the Congress and its allies would form the next government, but left the door open for the Left parties, saying 'all options are open'. 'The Congress and its allies will form the next government,' Manmohan Singh said when asked whether he was optimistic about forming the next government.